3 results
The primary endopoint is to determine whether ketoconazole/octreotide combination therapy, followed by octreotide monotherapy, is an effective treatment for Cushing's disease. Secundary endpoints address the effects of this therapy on bone…
Objectives:Primary* Phase Ib: to determine the maximum tolerated dose (MTD) recommended for Phase II of eribulin mesylate (eribulin), administered in combination with gemcitabine plus cisplatin in patients with locally advanced or metastatic bladder…
The main objective of the first part of the study is the demonstration of 89Zr-cetuximab uptake in non-hepatic tumour lesions. The main objective of the second part is the association between 89Zr-cetuximab uptake in non-hepatic tumour lesions and…